PT  - JOURNAL ARTICLE
AU  - Daniels, Sarah
AU  - Wei, Hua
AU  - Denning, David W.
TI  - Platelet size as a predictor for severity and mortality in COVID-19 patients: a systematic review and meta-analysis
AID  - 10.1101/2021.07.15.21260576
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.15.21260576
4099  - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260576.short
4100  - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260576.full
AB  - Background Parameters reflecting platelet size can be sensitive indicators that circulating platelets are activated and COVID-19 patients are at increased risk of thrombosis. This systematic review aims to assess the association of mean platelet volume (MPV), platelet distribution width (PDW) and platelet-large cell ratio (P-LCR) with disease severity and mortality in COVID-19 patients.Methods English and Chinese databases were searched electronically to identify studies reporting data on MPV, PDW or P-LCR in COVID-19 patients. Included articles underwent a quality rating. A meta-analysis was performed using the standard mean difference and interpreted as the common language effect size (CLES).Results Twenty-two studies (11,906 patients) were included in the meta-analysis. Of these, 14 were rated poor and eight were fair. The MPV and P-LCR was significantly higher at hospital admission in severe patients compared to non-severe patients. The MPV, PDW and P-LCR were significantly higher at hospital admission in non-survivors compared to survivors. There was a marked increase in the probability of a severe COVID-19 patient presenting with higher P-LCR at hospital admission than a non-severe patient (CLES: 68.7% [95% CI: 59.8%, 76.5%]), when compared with MPV and PDW ((CLES: 59.2% [95% CI: 53.1%, 65.1%]) and (CLES: 55.9% [95% CI: 50.6%, 62.2%]), respectively).Conclusion Severe COVID-19 disease is associated with the increased production of larger, younger platelets. When comparing MPV, PDW and P-LCR, P-LCR is the most important biomarker for evaluating platelet activity. P-LCR testing at hospital admission could identify COVID-19 patients with increased risk for thrombotic events, allowing preventative treatment.What is known on this topicThe incidence of thrombotic complications is high in COVID-19 patients with severe disease.Parameters reflecting platelet size can be sensitive indicators that circulating platelets are activated and that COVID-19 patients are at increased risk of thrombosis.What does this paper addWhen compared to MPV and PDW, P-LCR is the most important biomarker for evaluating platelet activity in COVID-19 patients at hospital admission and could be used to identify patients with increased risk for thrombotic events.Current evidence is predominantly derived from retrospective design. Prospective studies are warranted to accurately determine cut-off values that may be used in the clinical setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data that is not presented in tables, figures or supplemental materials is available from the authors upon reasonable request.CENTRALCochrane Central Register of Controlled Trials CNKI China Knowledge Resource IntegratedCLESCommon language effect size COVID-19 Coronavirus disease 2019 ICU Intensive care unitIQRInterquartile rangeMPVMean platelet volumePDWPlatelet distribution widthP-LCRPlatelet-large cell ratioPLTPlatelet countPRISMAPreferred Reporting Items for Systematic Reviews and Meta-AnalysesSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SDStandard deviationSMDStandardized mean difference